Insights from 2024 EHA Annual Meeting

 

Insights from 2024 EHA Annual Meeting
E

EHA 2024 Insights: Relationship Between Hemoglobin and QoL in Transfusion-Dependent Patients With LR-MDS Receiving Luspatercept or Epoetin Alfa

By Insights from 2024 EHA Annual Meeting FEATURING Esther Oliva
By Insights from 2024 EHA Annual Meeting FEATURING Esther Oliva
16 views
July 26, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Videos
15:07
2024 ASCO® Annual Meeting Insights Hub

Highlights of Recent Updates in CML: Impact on Practice

Feat. E. Atallah
10:39
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: OMS906, a Novel MASP-3 Inhibitor, in PNH Patients…

Feat. M. Griffin
19:09
International CML Foundation

Biological Highlights in CML From EHA

Feat. N. Cross
16:02
International CML Foundation

Clinical Highlights in CML From EHA

Feat. A. Hochhaus
13:38
Insights from 2024 EHA Annual Meeting

Top 5 Impactful MPN Abstracts From Summer Conferences

Feat. P. Bose
06:45
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Relationship Between Hemoglobin and QoL in Transf…

Feat. E. Oliva
02:01
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Feat. E. Angelucci
14:27
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Limited Stage HL - Current SOC, Future Directions…

Feat. S. Park
07:33
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sonrotoclax and Zanubrutinib Combination Therapy …

Feat. C. Tam
13:17
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients…

Feat. M. Hoffmann
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
14:47
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin&#x…

Feat. M. Salamoon
13:58
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Feat. M. Salamoon
06:03
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Zanubrutinib vs. Acalabrutinib in B-cell Malignan…

Feat. T. Munir
09:15
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Low-Molecular-Weight Heparin and VTE in Newly Dia…

Feat. M. Lauw
06:55
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Results by Cytogenetic Risk From PERSEUS - Dara-V…

Feat. M. Dimopoulos
06:31
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Impact of Anemia on Clinical Outcomes in MF Patie…

Feat. H. Kathrin Al-Ali
08:01
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL

Feat. S. Opat
14:32
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Infectious Complications in BCMA- and GPRC5D-Targ…

Feat. J. Mersi
03:52
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Fa…

Feat. G. Borthakur
04:03
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma

Feat. W. Jurczak
05:27
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Updated Trends in Real-World Outpatient Administr…

Feat. R. Bansal
06:39
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Axicabtagene Ciloleucel in R/R Primary Mediastina…

Feat. J. Galtier
12:32
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sequential Administration of Bispecific Antibodie…

Feat. D. Fandrei
06:51
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL W…

Feat. W. Jurczak
10:03
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax f…

Feat. P. Ghia
12:04
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: The Impact of TP53 Mutation Burden on Risk & …

Feat. M. Salamoon
06:54
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory W…

Feat. M. Shadman
05:41
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in H…

Feat. C. Coombs
06:30
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ A…

Feat. E. Oliva
11:23
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated …

Feat. J. Cortés
14:39
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: REVIVE Study - Updated Long-Term Results of Hepci…

Feat. K. Pettit
04:33
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Daratumumab for iTTP

Feat. J. Weisinger
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
09:52
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors

Feat. J. Zeidner
11:40
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R A…

Feat. W. Jen
10:27
Insights from 2024 EHA Annual Meeting

Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib i…

Feat. J. Ribera
19:14
2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

Feat. K. Rogers, J. Woyach
07:38
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - A…

Feat. M. Kamdar
12:24
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transpl…

Feat. P. Sonneveld
12:00
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in …

Feat. M. Teresa Voso